Experience with Netakimab and a GLP-1 agonist in patients with psoriasis and metabolic syndrome

Understanding the pathogenetic relationship between psoriasis and obesity is crucial, as excess weight can reduce the effectiveness of medications, highlighting its clinical significance not only in the context of disease severity but also in relation to therapeutic outcomes, including with the use of genetically engineered biological therapies. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a class of drugs that act on incretin hormone pathways, normalizing metabolic disorders. Clinical trials have been published on the use of GLP-1 agonists in patients with psoriasis. In this context, studying the combined use of genetically engineered drugs and GLP-1 agonists in patients with psoriasis and associated metabolic syndrome is relevant. Material and methods. Twelve patients with psoriasis and metabolic syndrome were observed. All patients were prescribed netakimab 120 mg and tirzepatide according to the package insert. Results. The PASI index (PASI) scores were statistically significant (p